Literature DB >> 16932712

Mechanisms of Disease: the complement system and the pathogenesis of systemic lupus erythematosus.

H Terence Cook1, Marina Botto.   

Abstract

Complement activation is common in patients with systemic lupus erythematosus (SLE), resulting in hypocomplementemia and deposition of complement at sites of tissue damage. The availability of mice with specific deficiencies of components of the complement system has provided new insights into the mechanisms by which complement might be involved in autoimmunity and tissue injury in SLE. In humans, deficiencies of early components of the classical complement pathway are strongly associated with SLE. Mice lacking C1q or C4 are also predisposed to autoimmunity, which is associated with the failure of normal clearance of apoptotic cells bearing on their surfaces many of the autoantigens involved in SLE. Antiphospholipid syndrome is common in patients with SLE and studies in an animal model of fetal loss caused by antiphospholipid syndrome have shown that injury is dependent on activation of complement with subsequent neutrophil influx and synthesis of tumor necrosis factor. Insights from animal models might enable the design of more rational therapeutic approaches for manipulating the complement system in human SLE.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16932712     DOI: 10.1038/ncprheum0191

Source DB:  PubMed          Journal:  Nat Clin Pract Rheumatol        ISSN: 1745-8382


  50 in total

Review 1.  Role of TWEAK in lupus nephritis: a bench-to-bedside review.

Authors:  Jennifer S Michaelson; Nicolas Wisniacki; Linda C Burkly; Chaim Putterman
Journal:  J Autoimmun       Date:  2012-06-22       Impact factor: 7.094

Review 2.  Harnessing programmed cell death as a therapeutic strategy in rheumatic diseases.

Authors:  Madhu Ramaswamy; Min Deng; Richard M Siegel
Journal:  Nat Rev Rheumatol       Date:  2011-02-01       Impact factor: 20.543

Review 3.  Complement regulators and inhibitory proteins.

Authors:  Peter F Zipfel; Christine Skerka
Journal:  Nat Rev Immunol       Date:  2009-09-04       Impact factor: 53.106

4.  Cofactors required for TLR7- and TLR9-dependent innate immune responses.

Authors:  Chih-Yuan Chiang; Alex Engel; Amanda M Opaluch; Irene Ramos; Ana M Maestre; Ismael Secundino; Paul D De Jesus; Quy T Nguyen; Genevieve Welch; Ghislain M C Bonamy; Loren J Miraglia; Anthony P Orth; Victor Nizet; Ana Fernandez-Sesma; Yingyao Zhou; Gregory M Barton; Sumit K Chanda
Journal:  Cell Host Microbe       Date:  2012-03-15       Impact factor: 21.023

5.  Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus.

Authors:  Jung-Yoon Choe; Seong-Kyu Kim
Journal:  Inflamm Res       Date:  2016-02-26       Impact factor: 4.575

Review 6.  The role of defective clearance of apoptotic cells in systemic autoimmunity.

Authors:  Luis E Muñoz; Kirsten Lauber; Martin Schiller; Angelo A Manfredi; Martin Herrmann
Journal:  Nat Rev Rheumatol       Date:  2010-05       Impact factor: 20.543

7.  Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus.

Authors:  Gang Wang; Lai-Shan Tam; Bonnie Ching-Ha Kwan; Edmund Kwok-Ming Li; Kai-Ming Chow; Cathy Choi-Wan Luk; Philip Kam-Tao Li; Cheuk-Chun Szeto
Journal:  Clin Rheumatol       Date:  2011-10-07       Impact factor: 2.980

8.  Detection of dynamic frequencies of Th17 cells and their associations with clinical parameters in patients with systemic lupus erythematosus receiving standard therapy.

Authors:  Zhenke Wen; Lin Xu; Wei Xu; Sidong Xiong
Journal:  Clin Rheumatol       Date:  2014-05-10       Impact factor: 2.980

9.  Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist.

Authors:  Scott E Wenderfer; Stanislaw M Stepkowski; Michael C Braun
Journal:  Kidney Int       Date:  2008-09-03       Impact factor: 10.612

10.  The regulation of liver cell survival by complement.

Authors:  Maciej M Markiewski; Robert A DeAngelis; Christoph W Strey; Periklis G Foukas; Craig Gerard; Norma Gerard; Rick A Wetsel; John D Lambris
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.